U.S. markets open in 6 hours 8 minutes
  • S&P Futures

    3,666.00
    -1.25 (-0.03%)
     
  • Dow Futures

    29,859.00
    -9.00 (-0.03%)
     
  • Nasdaq Futures

    12,480.50
    +26.25 (+0.21%)
     
  • Russell 2000 Futures

    1,835.30
    -2.20 (-0.12%)
     
  • Crude Oil

    45.36
    +0.08 (+0.18%)
     
  • Gold

    1,844.80
    +14.60 (+0.80%)
     
  • Silver

    24.34
    +0.26 (+1.10%)
     
  • EUR/USD

    1.2133
    +0.0018 (+0.15%)
     
  • 10-Yr Bond

    0.9480
    0.0000 (0.00%)
     
  • Vix

    21.17
    +0.40 (+1.93%)
     
  • GBP/USD

    1.3401
    +0.0025 (+0.19%)
     
  • USD/JPY

    104.3400
    -0.0840 (-0.08%)
     
  • BTC-USD

    19,296.40
    +347.15 (+1.83%)
     
  • CMC Crypto 200

    378.25
    +13.34 (+3.66%)
     
  • FTSE 100

    6,463.23
    -0.16 (-0.00%)
     
  • Nikkei 225

    26,809.37
    +8.39 (+0.03%)
     

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Zosano Pharma Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 28, 2020 - ZSAN

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - November 16, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Zosano Pharma Corporation ("Zosano") (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Northern District of California. To get more information go to:

https://www.zlk.com/pslra-1/zosano-pharma-corporation-loss-submission-form?prid=10980&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the Company's clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company's New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company's lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

If you suffered a loss in Zosano you have until December 28, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68318